# Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected

> **NCT05075044** · PHASE4 · UNKNOWN · sponsor: **China National Biotec Group Company Limited** · enrollment: 400 (estimated)

## Conditions studied

- HIV Infections
- COVID-19

## Interventions

- **BIOLOGICAL:** Inactivated COVID-19 vaccine

## Key facts

- **NCT ID:** NCT05075044
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-08
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2021-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075044, "Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05075044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*